JPS5874608A - アヘン製剤に関して末梢「きつ」抗作用を有する製薬組成物 - Google Patents
アヘン製剤に関して末梢「きつ」抗作用を有する製薬組成物Info
- Publication number
- JPS5874608A JPS5874608A JP57177719A JP17771982A JPS5874608A JP S5874608 A JPS5874608 A JP S5874608A JP 57177719 A JP57177719 A JP 57177719A JP 17771982 A JP17771982 A JP 17771982A JP S5874608 A JPS5874608 A JP S5874608A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- morphine
- active ingredient
- peripheral
- antagonism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 230000002093 peripheral effect Effects 0.000 title claims abstract description 10
- 230000008485 antagonism Effects 0.000 title description 9
- 239000003814 drug Substances 0.000 title description 5
- 239000008896 Opium Substances 0.000 title 1
- 229960001027 opium Drugs 0.000 title 1
- 229940127240 opiate Drugs 0.000 claims abstract description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 6
- 230000003042 antagnostic effect Effects 0.000 claims abstract description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract 2
- 229910052794 bromium Inorganic materials 0.000 claims abstract 2
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 2
- 239000000460 chlorine Substances 0.000 claims abstract 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims description 8
- 150000004767 nitrides Chemical group 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 16
- OZYUPQUCAUTOBP-QXAKKESOSA-N Levallorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(CC=C)[C@@H]2CC2=CC=C(O)C=C21 OZYUPQUCAUTOBP-QXAKKESOSA-N 0.000 abstract 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 abstract 1
- 229960000263 levallorphan Drugs 0.000 abstract 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 37
- 229960005181 morphine Drugs 0.000 description 18
- 230000000694 effects Effects 0.000 description 12
- 230000000202 analgesic effect Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 206010010774 Constipation Diseases 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 239000003610 charcoal Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229940014259 gelatin Drugs 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- -1 allyl halide Chemical class 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 229960004127 naloxone Drugs 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009291 secondary effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000010215 titanium dioxide Nutrition 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 2
- 235000012732 erythrosine Nutrition 0.000 description 2
- 239000004174 erythrosine Substances 0.000 description 2
- 229940011411 erythrosine Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 229960005196 titanium dioxide Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QEIXJGGCWUIRNP-ZPUUBZGTSA-N (8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;[(8s,13s,14s,17s)-13-methyl-3-oxo-2,6,7,8,14,15,16,17-octahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@H](OC(=O)C)[C@@]1(C)C=C2 QEIXJGGCWUIRNP-ZPUUBZGTSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- OSDWBNJEKMUWAV-UHFFFAOYSA-N Allyl chloride Chemical compound ClCC=C OSDWBNJEKMUWAV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- ZSBDPRIWBYHIAF-UHFFFAOYSA-N N-acetyl-acetamide Natural products CC(=O)NC(C)=O ZSBDPRIWBYHIAF-UHFFFAOYSA-N 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- HFEHLDPGIKPNKL-UHFFFAOYSA-N allyl iodide Chemical compound ICC=C HFEHLDPGIKPNKL-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- RIOXQFHNBCKOKP-UHFFFAOYSA-N benomyl Chemical compound C1=CC=C2N(C(=O)NCCCC)C(NC(=O)OC)=NC2=C1 RIOXQFHNBCKOKP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 1
- 229960005286 carbaryl Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 230000001379 nervous effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940051862 revalor Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8119607 | 1981-10-19 | ||
| FR8119607A FR2514644A1 (fr) | 1981-10-19 | 1981-10-19 | Composition pharmaceutique a action antagoniste peripherique des opiaces |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS5874608A true JPS5874608A (ja) | 1983-05-06 |
Family
ID=9263165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57177719A Pending JPS5874608A (ja) | 1981-10-19 | 1982-10-12 | アヘン製剤に関して末梢「きつ」抗作用を有する製薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4489079A (enExample) |
| EP (1) | EP0077723B1 (enExample) |
| JP (1) | JPS5874608A (enExample) |
| AT (1) | ATE17942T1 (enExample) |
| AU (1) | AU559451B2 (enExample) |
| DE (1) | DE3269082D1 (enExample) |
| FR (1) | FR2514644A1 (enExample) |
| IL (1) | IL66853A (enExample) |
| NZ (1) | NZ202210A (enExample) |
| ZA (1) | ZA827063B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2547820B1 (fr) * | 1983-06-24 | 1986-04-18 | Midy Spa | Antagonistes peripheriques des opiaces |
| US5624958A (en) * | 1987-12-31 | 1997-04-29 | Isaacs; Charles E. | Disinfecting contact lenses |
| US5552406A (en) * | 1994-06-17 | 1996-09-03 | The Mclean Hospital Corporation | Method for treating pain and brain perfusion abnormalities using mixed opioid agonist-antagonists |
| DE19752080A1 (de) * | 1997-11-25 | 1999-07-29 | Karlsruhe Forschzent | Verfahren zur Herstellung eines mehrkomponentigen, oxidischen Keramikpulvers |
| US6469030B2 (en) * | 1999-11-29 | 2002-10-22 | Adolor Corporation | Methods for the treatment and prevention of ileus |
| EP1244448B1 (en) * | 1999-11-29 | 2009-05-27 | Adolor Corporation | Novel methods for the treatment and prevention of ileus |
| DK2939696T3 (en) * | 2001-10-18 | 2016-05-23 | Nektar Therapeutics | Polymer Conjugates of Opioid Antagonists |
| US20050191340A1 (en) * | 2002-08-09 | 2005-09-01 | Gruenenthal Gmbh | Opioid-receptor antagonists in transdermal systems having buprenorphine |
| DK1694363T3 (en) * | 2003-12-16 | 2014-03-24 | Nektar Therapeutics | Monodisperse PEGylated Naloxole Compositions |
| EP2190819B1 (en) | 2007-08-09 | 2016-05-25 | Rensselaer Polytechnic Institute | Quaternary opioid carboxamides |
| NZ600379A (en) | 2009-12-04 | 2014-05-30 | Alkermes Pharma Ireland Ltd | Morphinan derivatives for the treatment of drug overdose |
| US8436175B2 (en) * | 2010-03-22 | 2013-05-07 | Rensselaer Polytechnic Institute | Carboxamide bioisosteres of opiates |
| SI3446565T1 (sl) | 2010-08-23 | 2024-03-29 | Alkermes Pharma Ireland Limited | Metode zdravljenja povečanja teže, povzročene z antipsihotiki |
| RS56181B1 (sr) | 2011-06-29 | 2017-11-30 | Alkermes Inc | Periferno delujuća opioidna jedinjenja |
| US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| US9656961B2 (en) | 2013-05-24 | 2017-05-23 | Alkermes Pharma Ireland Limited | Methods for treating depressive symptoms |
| JP2016519161A (ja) | 2013-05-24 | 2016-06-30 | アルカームス ファーマ アイルランド リミテッド | モルファン及びモルフィナン類似物及び使用の方法 |
| EP4243768A1 (en) | 2020-11-12 | 2023-09-20 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4176186A (en) * | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
-
1981
- 1981-10-19 FR FR8119607A patent/FR2514644A1/fr active Granted
-
1982
- 1982-09-22 IL IL66853A patent/IL66853A/xx unknown
- 1982-09-24 US US06/422,568 patent/US4489079A/en not_active Expired - Fee Related
- 1982-09-27 ZA ZA827063A patent/ZA827063B/xx unknown
- 1982-09-30 AU AU88922/82A patent/AU559451B2/en not_active Expired - Fee Related
- 1982-10-12 JP JP57177719A patent/JPS5874608A/ja active Pending
- 1982-10-13 DE DE8282401876T patent/DE3269082D1/de not_active Expired
- 1982-10-13 AT AT82401876T patent/ATE17942T1/de not_active IP Right Cessation
- 1982-10-13 EP EP82401876A patent/EP0077723B1/fr not_active Expired
- 1982-10-18 NZ NZ202210A patent/NZ202210A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL66853A0 (en) | 1982-12-31 |
| ZA827063B (en) | 1983-07-27 |
| AU559451B2 (en) | 1987-03-12 |
| US4489079A (en) | 1984-12-18 |
| EP0077723B1 (fr) | 1986-02-12 |
| FR2514644B1 (enExample) | 1984-04-20 |
| IL66853A (en) | 1985-08-30 |
| DE3269082D1 (en) | 1986-03-27 |
| AU8892282A (en) | 1983-04-28 |
| NZ202210A (en) | 1985-03-20 |
| FR2514644A1 (fr) | 1983-04-22 |
| ATE17942T1 (de) | 1986-02-15 |
| EP0077723A1 (fr) | 1983-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS5874608A (ja) | アヘン製剤に関して末梢「きつ」抗作用を有する製薬組成物 | |
| DE69610323T2 (de) | Sich schnell im munde auflösende zusammensetzungen für dopaminagonisten | |
| RU2552786C2 (ru) | Жидкий назальный спрей, содержащий налтрексон в низкой дозе | |
| JP2003514013A (ja) | 医薬組成物 | |
| CZ284928B6 (cs) | Použití riluzolu pro výrobu léčiva určeného k léčení Parkinsonovy choroby a Parkinsonových syndromů | |
| KR20060017570A (ko) | 무호흡증, 대식증, 다른 질환을 치료하기 위한 광학적으로순수한 (+)-노르씨사프라이드의 용도 | |
| BRPI0406674B1 (pt) | composição para a ministração intranasal de fentanila ou um seu sal farmaceuticamente aceitável, uso de uma composição, dispositivo para pulverização, e, processo para preparar uma composição | |
| US4210670A (en) | Antithrombotic agents | |
| JPH11501282A (ja) | コリン受容体作用薬及び拮抗薬としてのエピバチジン及びその誘導体 | |
| AU687481B2 (en) | Neuromuscular blocking agents | |
| JPS6322520A (ja) | 学習促進・記憶増強用薬剤 | |
| KR20010032009A (ko) | 수면성 무호흡의 치료에 미타자핀을 사용하는 방법 | |
| JP2002538102A (ja) | 光学的に純粋なｒ（＋）オンダンセトロンを使用する無呼吸および無呼吸障害の治療方法 | |
| EP0526540B1 (en) | Use of 5-ht4-receptor antagonists in the treatment of atrial fibrillation, including the prevention of stroke | |
| NO309965B1 (no) | Oralt farmasøytisk antihostepreparat | |
| US2817623A (en) | Tabernanthine, ibogaine containing analgesic compositions | |
| EP0471388B1 (de) | Mittel zur Behandlung der Herzinsuffizienz | |
| KR100352898B1 (ko) | 새로운3-벤조일-3,7-디아자바이사이클로[3,3,1]노난-화합물을함유하는약제 | |
| JP2001526217A (ja) | 血管性頭痛に対する局所麻酔薬の新規な使用 | |
| CN103735545B (zh) | 左旋奥拉西坦、奥拉西坦在制备预防或治疗昏迷药物中的应用 | |
| US4370331A (en) | L-Glaucine containing composition for cough relief | |
| EP1038526A1 (de) | Behandlung von funktionellen Störungen der unteren Darmwege und einhergehenden visceralen Schmerzen mit Moxonidin | |
| US4028467A (en) | Analgesic compositions comprising levo-propoxyphene and benzo diazepine and process | |
| US3954986A (en) | Pharmaceutical composition having synergistic analgesic activity | |
| EP3141264A1 (en) | Pharmaceutical preparation for masked taste oral administration, containing clomipramine |